Insulet: CEO History

Insulet Corporation (NASDAQ: PODD) is an innovative medical device company based in Acton, Massachusetts, dedicated to improving the lives of people with diabetes and other conditions through its revolutionary Omnipod product platform. Founded in 2000, Insulet eliminated the cumbersome plastic tubing that connected conventional insulin pumps to patient infusion sites. Instead, Insulet engineered a small, lightweight, waterproof pod that adheres directly to the skin, delivering continuous subcutaneous insulin without external tubes. The company's flagship innovation, the Omnipod 5 Automated Insulin Delivery (AID) System, represents a breakthrough in type 1 and type 2 diabetes management: it embeds SmartAdjust automated glycemic algorithms directly inside the wearable pod, communicating wirelessly with continuous glucose monitors (such as Dexcom G6/G7 and Abbott FreeStyle Libre 2 Plus) to adjust insulin dosing automatically every five minutes based on real-time glucose trends. Led by President and CEO Jim Hollingshead, Insulet serves more than 420,000 active customers globally, generating over $2.0 billion in annual revenue with sustained double-digit growth. A key structural differentiator is Insulet's pay-as-you-go pharmacy distribution model, which allows patients to acquire pods with predictable monthly copays at retail pharmacies, completely bypassing the complex four-year insurance lock-in and heavy upfront equipment expenses required by durable medical equipment (DME) pump manufacturers. Insulet represents an institutional pillar within its global sector, maintaining expansive operations, robust customer and partner relationships, and mission-critical operating infrastructure. Operating on a significant scale across domestic and international markets, Insulet continues to expand its technological and operational capabilities, integrating automated digital workflows, enterprise-grade data security protocols, and advanced operational systems to maximize service reliability and long-term operating efficiency. The enterprise remains focused on capital discipline, scalable operational economics, and strategic customer expansion across high-value market segments. continuous investment in specialized research, modern distribution networks, and skilled workforce development enables Insulet to anticipate regulatory changes, mitigate emerging market risks, and deliver dependable performance for millions of clients, patients, or consumers worldwide.